330 related articles for article (PubMed ID: 26190565)
41. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
Sriwastava S; Kataria S; Srivastava S; Kazemlou S; Gao S; Wen S; Saber H; Tripathi R; Sheikh Z; Peterson S; Gwinn R; Bernitsas E
J Neuroimmunol; 2021 Nov; 360():577721. PubMed ID: 34547511
[TBL] [Abstract][Full Text] [Related]
42. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG
PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921
[TBL] [Abstract][Full Text] [Related]
43. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
Berger JR; Malik V; Lacey S; Brunetta P; Lehane PB
J Neurovirol; 2018 Jun; 24(3):323-331. PubMed ID: 29508305
[TBL] [Abstract][Full Text] [Related]
44. Age-Dependent Seroprevalence of JCV Antibody in Children.
Hennes EM; Kornek B; Huppke P; Reindl M; Rostasy K; Berger T
Neuropediatrics; 2016 Apr; 47(2):112-4. PubMed ID: 26479766
[TBL] [Abstract][Full Text] [Related]
45. Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics.
Verheyen J; Maizus K; Feist E; Tolman Z; Knops E; Saech J; Spengler L; Waterboer T; Burmester GR; Pawlita M; Pfister H; Rubbert-Roth A
Med Microbiol Immunol; 2015 Oct; 204(5):613-8. PubMed ID: 25678083
[TBL] [Abstract][Full Text] [Related]
46. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
McGuigan C; Craner M; Guadagno J; Kapoor R; Mazibrada G; Molyneux P; Nicholas R; Palace J; Pearson OR; Rog D; Young CA
J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):117-25. PubMed ID: 26492930
[TBL] [Abstract][Full Text] [Related]
47. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
Laroni A; Giacomazzi CG; Grimaldi L; Gallo P; Sormani MP; Bertolotto A; McDermott JL; Gandoglia I; Martini I; Vitello G; Rinaldi F; Barzon L; Militello V; Pizzorno M; Bandini F; Capello E; Palù G; Uccelli A; Mancardi GL; Varnier OE
J Neuroimmune Pharmacol; 2012 Sep; 7(3):665-72. PubMed ID: 22585413
[TBL] [Abstract][Full Text] [Related]
48. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study.
Arkema EV; van Vollenhoven RF; Askling J;
Ann Rheum Dis; 2012 Nov; 71(11):1865-7. PubMed ID: 22739991
[TBL] [Abstract][Full Text] [Related]
49. Progressive multifocal leukoencephalopathy in autoimmune diseases.
Palazzo E; Yahia SA
Joint Bone Spine; 2012 Jul; 79(4):351-5. PubMed ID: 22281228
[TBL] [Abstract][Full Text] [Related]
50. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
[TBL] [Abstract][Full Text] [Related]
51. Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab.
Flores J; Anguiano O; Rivas-Alonso V; González-Conchillos H; Pérez-Saldivar M; Sotelo J; Magaña-Maldonado R; Quiñones S; Corona T; Olivares H; Hernández-González O; Martínez-Palomo A; Treviño I; Ordoñez G
Mult Scler Relat Disord; 2021 Nov; 56():103266. PubMed ID: 34555758
[TBL] [Abstract][Full Text] [Related]
52. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.
Fleischmann RM
Arthritis Rheum; 2009 Nov; 60(11):3225-8. PubMed ID: 19877057
[TBL] [Abstract][Full Text] [Related]
53. Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies.
Sgarlata E; Chisari CG; Toscano S; Finocchiaro C; Lo Fermo S; Millefiorini E; Patti F
Curr Neuropharmacol; 2022; 20(10):1978-1987. PubMed ID: 34766895
[TBL] [Abstract][Full Text] [Related]
54. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
[TBL] [Abstract][Full Text] [Related]
55. JCV epidemiology in MS (JEMS)--epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients--Portuguese data.
da Silva AM; Santos ME;
J Neurol Sci; 2014 Feb; 337(1-2):119-22. PubMed ID: 24369270
[TBL] [Abstract][Full Text] [Related]
56. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
Bossolasco S; Calori G; Moretti F; Boschini A; Bertelli D; Mena M; Gerevini S; Bestetti A; Pedale R; Sala S; Sala S; Lazzarin A; Cinque P
Clin Infect Dis; 2005 Mar; 40(5):738-44. PubMed ID: 15714422
[TBL] [Abstract][Full Text] [Related]
58. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
Hunt D; Giovannoni G
Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
[TBL] [Abstract][Full Text] [Related]
59. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Faulkner M
Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
[TBL] [Abstract][Full Text] [Related]
60. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
Baber U; Bouley A; Egnor E; Sloane JA
J Neurol; 2018 Oct; 265(10):2342-2345. PubMed ID: 30109480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
